MARKET

HELP

HELP

Cybin Inc
NASDAQ
11.51
+0.41
+3.69%
Opening 15:39 08/07 EDT
OPEN
11.21
PREV CLOSE
11.10
HIGH
11.59
LOW
11.05
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
11.59
52 WEEK LOW
3.760
MARKET CAP
713.44M
P/E (TTM)
-3.7723
1D
5D
1M
3M
1Y
5Y
1D
Psychedelic: Compass Pathways, GH Research report quarterly earnings
TipRanks · 1d ago
Helus Pharma appoints Michael Halstead as CEO
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (ARVN), Certara (CERT) and Helus Pharma (HELP)
TipRanks · 2d ago
Helus Pharma Names Former Intra-Cellular President Michael Halstead as CEO Amid Phase 3 MDD Push
TipRanks · 4d ago
Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety
PUBT · 4d ago
Helus Pharma names ex-Intra-Cellular executive Michael Halstead as CEO
Seeking Alpha · 4d ago
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
Benzinga · 4d ago
HELUS PHARMA - TOPLINE DATA FROM PHASE 3 HLP003 STUDY FOR MDD EXPECTED IN Q4 2026
Reuters · 4d ago
More
About HELP
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Webull offers Cybin Inc stock information, including NASDAQ: HELP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HELP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HELP stock methods without spending real money on the virtual paper trading platform.